- Home
- SPFI vs OCS Comparison
SPFI vs OCS Comparison
Compare SPFI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | OCS |
|---|---|---|
| Founded | 1941 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 843.2M | 732.4M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SPFI | OCS |
|---|---|---|
| Price | $44.11 | $10.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $46.00 | $42.00 |
| AVG Volume (30 Days) | 93.0K | ★ 162.0K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | $466.06 |
| Revenue Next Year | $9.40 | $479.73 |
| P/E Ratio | $24.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.34 | $9.65 |
| 52 Week High | $46.94 | $34.48 |
Technical Indicators
Market Signals| Indicator | SPFI | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 23.91 |
| Support Level | $44.05 | N/A |
| Resistance Level | $45.56 | $13.49 |
| Average True Range (ATR) | 0.82 | 0.56 |
| MACD | -0.09 | -0.18 |
| Stochastic Oscillator | 36.66 | 13.62 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.